AIMS: We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. METHODS: Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. RESULTS: Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. CONCLUSIONS: Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.
AIMS: We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. METHODS: Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. RESULTS: Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. CONCLUSIONS: Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.
Authors: Patricia A Sheridan; Heather A Paich; Jean Handy; Erik A Karlsson; Stacey Schultz-Cherry; Michael Hudgens; Sam Weir; Terry Noah; Melinda A Beck Journal: Vaccine Date: 2015-06-01 Impact factor: 3.641
Authors: Jungmin Son; Soo Bong Lee; Dong Won Lee; Il Young Kim; Su Jin Lee; Sun Min Lee; Sang Heon Song; Eun Young Seong; Ihm Soo Kwak Journal: Clin Exp Nephrol Date: 2012-09-19 Impact factor: 2.801
Authors: Yu Bin Seo; Ji Hyeon Baek; Jacob Lee; Joon Young Song; Jin Soo Lee; Hee Jin Cheong; Woo Joo Kim Journal: Clin Vaccine Immunol Date: 2015-09-16
Authors: Christine E Mathews; Eric L Brown; Perla J Martinez; Upasana Bagaria; Moon H Nahm; Robert L Burton; Susan P Fisher-Hoch; Joseph B McCormick; Shaper Mirza Journal: Clin Vaccine Immunol Date: 2012-07-03
Authors: Sarah Spencer; Jessie R Chung; Edward A Belongia; Maria Sundaram; Jennifer Meece; Laura A Coleman; Richard K Zimmerman; Mary Patricia Nowalk; Krissy Moehling Geffel; Ted Ross; Chalise E Carter; David Shay; Min Levine; Justine Liepkalns; Jin Hyang Kim; Suryaprakash Sambhara; Mark G Thompson; Brendan Flannery Journal: Influenza Other Respir Viruses Date: 2021-12-03 Impact factor: 4.380